Correction to: Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study (Neurotherapeutics, (2022), 19, 4, (1248-1258), 10.1007/s13311-022-01237-4)

Michael Benatar, Joanne Wuu, Peter M. Andersen, Robert C. Bucelli, Jinsy A. Andrews, Markus Otto, Nita A. Farahany, Elizabeth A. Harrington, Weiping Chen, Adele A. Mitchell, Toby Ferguson, Sheena Chew, Liz Gedney, Sue Oakley, Jeong Heo, Sowmya Chary, Laura Fanning, Danielle Graham, Peng Sun, Yingying LiuJanice Wong, Stephanie Fradette

Research output: Contribution to journalComment/debate

Abstract

Due to an error during production, captions for Fig. 1, Fig. 5 and Fig. 6 in this article were formatted in a confusing manner in this article as originally published. The original article has been corrected.

Original languageEnglish
Pages (from-to)1686
Number of pages1
JournalNeurotherapeutics
Volume19
Issue number5
DOIs
StatePublished - Sep 2022

Fingerprint

Dive into the research topics of 'Correction to: Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study (Neurotherapeutics, (2022), 19, 4, (1248-1258), 10.1007/s13311-022-01237-4)'. Together they form a unique fingerprint.

Cite this